Blood and Bone Marrow Transplant

Short Name	Comments	Type	Investigator	Contact
BMT Cord Blood Access Protocol	**A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications**	Treatment	**SHORE:** Dr. Troy Quigg	**Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
NYBB UCB	**A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients**	Treatment	**SHORE:** Dr. Troy Quigg	**Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
2018-051 Cardiac Strain	**Utility of Serial Echocardiogram Parameters to Assess Cardiotoxicity and Evaluate Cardio-Protective Therapy in Adult Blood and Marrow Transplant Patients (Adult BMT)**	Other	**SHORE**: Dr. Sami Brake	**Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
2019-118: Ruxolitinib EA	**An Open-label, Expanded Access Program of Ruxolitinib for the Treatment of Graft vs Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant**	Treatment	**SHORE**: Dr. Sami Brake	**Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
Kymriah EAP/MAP	**Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Large B Cell Lymphoma Patients with out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel out of Specification for Commercial Release**	Treatment	**SHORE**: Drs. Sami Brake, Ulrich Duffner, Troy Quigg	**Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125

GRAVITAS 309	**A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host-Disease**	Treatment	**SHORE**: Dr. Sami Brake	**Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
2013-024	**10-CMSMDS-1 (MDS Study and MCR)**	Other	**SHORE:** Dr. Troy Quigg	**Josh Haveman** josh.haveman@spectrumhealth.org 616.329.2724
2013-024	**16-CMS-MF (Myelofribrosis Study and MCR)**	Other	**SHORE:** Dr. Troy Quigg	**Josh Haveman** josh.haveman@spectrumhealth.org 616.329.2724
2013-024	**17-CMS-SCD (Sickle Cell Study and MCR)**	Other	**SHORE:** Dr. Troy Quigg	**Josh Haveman** josh.haveman@spectrumhealth.org 616.329.2724
2013-024	**17-CMS-MM (Multiple Myeloma and Allo Transplant Study and MCR**	Other	**SHORE:** Dr. Troy Quigg	**Josh Haveman** josh.haveman@spectrumhealth.org 616.329.2724
	SC17-10 (ALL/PASS Study)	Treatment	**SHORE:** Dr. Troy Quigg	**Josh Haveman** josh.haveman@spectrumhealth.org 616.329.2724

	SC16-040 (HL/Nivolumab)	Other	**SHORE:** Dr. Troy Quigg	**Josh Haveman** josh.haveman@spectrumhealth.org 616.329.2724

Brain/CNS (Neurology)

Short Name	*Comments*	*Type*	*Investigator*	*Contact*
Glioma Registry	**Glioma Data Registry for Research**	Registry	**SHORE**: Dr. Todd Vitaz	**James Nelson** james.nelson@spectrumhealth.org 616.267.8277
2015-175	**NMTRC012 - PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy- A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy followed by maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma**	Treatment	**SHORE**: Dr. Deanna Mitchell	**Sarah Vos** sarah.vos@helendevoschildrens.org 616.486.2064 **Julie Steinbrecher** julie.steinbrecher@helendevoschildrens.org 616.267.1163
2016-258	**HEAD START 4 PROTOCOL: Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Embryonal Tumors. Clinical and Molecular Rish-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Randomization to Either Single-Cycle or to Three Sequential Cycles of Marrow-Ablativ Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue**	Treatment	**SHORE**: Dr. Albert Cornelius	**Sarah Vos** sarah.vos@helendevoschildrens.org 616.486.2064 **Julie Steinbrecher** julie.steinbrecher@helendevoschildrens.org 616.267.1163 **Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
NMTRC 014-NMTT	**NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)**	Treatment	**SHORE**: Dr. Deanna Mitchell	**Sarah Vos** sarah.vos@helendevoschildrens.org 616.486.2064 **Julie Steinbrecher** julie.steinbrecher@helendevoschildrens.org 616.267.1163

	A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma	Treatment	**SHORE**: Dr. Rebecca Loret de Mola	**Sarah Vos** sarah.vos@helendevoschildrens.org 616.486.2064 **Julie Steinbrecher** julie.steinbrecher@helendevoschildrens.org 616.267.1163 **Laura Paulsen** laura.paulsen@spectrumhealth.org 616.486.6125
NRG BN003	**Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A071401	**A Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ACNS1721	**A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ACNS1723	**Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients with Newly Diagnosed High Grade Glioma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A071701	**Genomically-guided Treatment Trial in Brain Metastases**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 19085	**A Phase II Clinical trial with Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy-induced Peripheral Neuropathy**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

ACNS1422	**A Phase II Study of Reduced Therapy for Newly Diagnosed Average-risk WNT-Driven Medulloblastoma Patients**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Short Name	Comments	Type	Investigator	Contact
CCTG MA.39	**Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NSABP B-51	**A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A011202	**A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotheraphy**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG BR003	**TRIPLE NEGATIVE; Adjuvant; HIGH RISK NODE(-)or NODE(+) / Invasive; A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A231901CD	**Improving Patient-Centered Communication in Breast Cancer: A RCT of A Shared Decision Engagement System (SHARES)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

S1418	**TRIPLE NEGATIVE: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Caqncer with >/=1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1703	**Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastic Hormone Recepter Postive Breast Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AFT-38 "Patina"	**A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2 - Positive Metastatic Breast Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1501	**A Phase III, Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her-2+ Breast Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA1151: TMIST	**Tomosynthesis Mammographic Imaging Screening Trial**	Other	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG BR002	**A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

NRG BR004	**A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ALLIANCE A221505	**Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 16070	**Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer**	Symptom Management	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
WF-97415	**Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)**	Prevention	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AFT-25 "Comet"	**AFT-25: A Phase III Prospective Randomized Trial Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A211601	**Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502**	Supportive Care	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

EA1181	**EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
Bolt	**BBI-20201001: A Phase I of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HRE2-Expressing Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554

Upper Gastrointestinal

Short Name	Comments	Type	Investigator	Contact
HAI for Pancreatic Mets	**A Phase II Trial of Hepatic Artery Infusional Floxuridine with Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases**	Treatment	**SHORE**: Dr. G. Paul Wright	**Marianne Morrissey** marianne.morrissey@spectrumhealth.org (616) 391-1129
EA2142	**Gastroenteropancreatic Neuroendocrine Carcinomas: Advanced G3 Non-Small Cell: Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2185	**Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs**	Other	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2183	**A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2187	**EA2187 - A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA8143	**A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

EA2176	**A Phase III Study of Immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2197	**Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S2001	**Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A021806	**A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AHEP1531	**Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2186 (GIANT)	**A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Novocure EF-27	**PANOVA 3: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant with Gemcitabine and Nab-paclitaxel**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
Lexicon (Tele-ABC)	**A Phase II, Multicenter, Open-label, Safety and Efficacy Study of Xermelo plus First-line Chemotherapy (Cis/Gem) in Patients with Locally Advanced, Unresectable, Recurrent, or Metastatic Biliary Tract Cancer (BTC)**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
QED (PROOF)	**A Phase III, Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus CIS/Gem (Gemcitabine with Cisplatin) in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
EMERALD 2	**A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Durvalumab, Monotherapy or in Combination, with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma who are at High Risk of Recurrence After Curative Hepatic Resection or**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
CP-MGAH22-06 (MAHOGANNY)	**A Phase II-III Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

NAPOLI-3	**An Open-label, Randomized, Multi-center, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-Fluorouracil/Leucovorin vs Nab-paclitaxel + Gemcitabine in Subjects who have not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
MK-7902	**MK-6482-011 : An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen. Has experienced disease progression on or after first- or second-line systemic treatment with an anti-PD-1/L1 therapy for locally advanced or metastatic RCC. The anti-PD-1/L1 therapy may have been monotherapy or in combination with other agent(s) such as antiCTLA4 or VEGF-targeted-TKI. The immediately preceding line of treatment has to have been an anti-PD-1/L1 therapy**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
MK-3475	**MK-6482-012: An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

Short Name	Comments	Type	Investigator	Contact
A021703	**Randomized Double-blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
WF-1806	**Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2182	**A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1613	**A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 16092	**A Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GI004	**Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

S0820	**A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflonithine and Sulindac (PACES)**	Prevention	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A021502	**ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer: A Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAQ162CD	**Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent**	Cancer Care Delivery	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2165	**A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
FC-11	**A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GI005	**Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Merck-4280	**MK-4280: A Phase I Trial of MK-4280 (LAG-3 Inhibitor) as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (Now in Expansion Cohort, All Patients get Pembrolizumab + LAG 3 Inhibitor (MK 4280)**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554
CRDF-01E	**An Expanded Access Program of Onvansertib in Combination with FOLFIRI and BBEVAcizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

Short Name	Comments	Type	Investigator	Contact
CISTO	**Comparison of Intravesical therapy and Surgery as Treatment Options for Bladder Cancer**	Observational	**SHORE** Dr. Brian Lane	**Zak Mulder** zachary.mulder@spectrumhealth.org 616.391.2724
WF-1802	**Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GU002	**NRG GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA8153	**Cabaz with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED 2 Trial**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A031102	**GERM CELL TUMORS/Relapsed or Refractory; Male Only; Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment. Phase III Trial**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

A031501	**Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AREN03B2	**COG-AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be <30 Years Old at the Time of Diagnosis**	Biobanking	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1802	**Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery Or Radiation) of The Primary Tumor in Metastatic Prostate Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A031803	**Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1806	**Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

A031704	**PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA8171	**Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer**	Treatment	**CRCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
AREN1921	**Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)**	Treatment	**CRCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
NRG CC007CD	**Increasing the Dose of Survivorship Care Planning In Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy**	Cancer Care Delivery	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GU005	**A Phase III IGRT + SBRT vs IGRT + Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA8143	**A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Merck 3475-641	**A Phase III, Randomized, Double-blind, Trial of Prembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
Merck MK 3475-921	**A Phase III, Randomized, Double-blind, Study of Pembrolizumab (MK-3475) Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
AstraZeneca (PREVAIL)	**A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression Using the Ventana SP263 Asasy in the First-line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma**	Other	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
AstraZeneca (NILE)	**A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer**	Biorepository	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

Gynecology

Short Name	Comments	Type	Investigator	Contact
NRG GY018	**A Phase III Randomized, Placebo-controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measureable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GY006	**Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer; Phase II; Radiation Therapy and Cisplatin Alone or in Combination with Intravenous *Triapine***	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GY005	**PLATINUM-RESISTANT OR -REFRACTORY OVARIAN, FALLOPIAN TUBE, OR PRIMARY/Recurrent, Randomized Phase II/III Study of the Combination of *Cediranib and Olaparib* Compared to Cediranib or Olaparib alone, or Standard of Care Chemotherapy**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
CC008	**A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GY009	**A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

STMW 2020.01	**Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRP-αFc-CD40L) Administered Intravenously in Subjects with Ovarian Cancer**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

Head and Neck

Short Name	Comments	Type	Investigator	Contact
EA3132	**Phase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
WF-97115	**HEAD & NECK: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia**	Symptom Management	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG HN005	**A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-stage, P16-Positive, Non-smoking Associated Oropharyngeal Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA3161	**A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
RTOG 1216	**Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Short Name	Comments	Type	Investigator	Contact
NHLBI-MDS	**National Myelodysplastic Syndromes (MDS) Study**	Registry	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1925	**Randomized, Phase III Study of Early Intervention With Venetoclax And Obinutuzumab Versus Delayed Therapy With Venetoclax And Obinutuzumab In Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A041702	**A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 YEARS OF AGE) with Chronic Lymphocytic Leukemia (CLL)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AALL1521	**A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AALL15P1	**A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

AALL1631	**International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AALL1732	**COG-AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-Lly**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AAML1531	**Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ACCL16N1CD	**Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL**	Cancer Care Delivery	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ALLIANCE: A041501	**A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A041701	**A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

S1318	**A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients = 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients = 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1712	**A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
Connect® MDS and AML	**The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry**	Registry	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
USC 9L-16-3	**A Phase II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, An Immune Checkpoint Inhibitor, in Patients with Intermediate or High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

Short Name	Comments	Type	Investigator	Contact
Wii Study	**Managing Fatigue Using Virtual Reality for Post-Operative Lung Cancer Patients: Understanding the Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Patient's Symptom Experience**	Treatment	**SHORE**: Drs. Geoffrey Lam and Charles Wilekes	**Cardiovascular Research Department** (616) 391-3886
2019-278 SEER-Lung	**A Prospective Blood Sample Collection Study to Develop and Validate a Panel of Protein-based Biomarkers in Patients with Pulmonary Nodules**	Other	**SHORE**: Dr. Glenn VanOtteren	**Tara Jager** (616) 391-5038 tara.jager@spectrumhealth.org
S1900E	**A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A151216	**Non-Squamous, Large IB, II or IIIA, any EGFR/ALK, Resected. Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial *(ALCHEMIST)***	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
E4512	**Must be enrolled in A151216. NSCLC; ALK+; Surgically Resected Early Stage. *Crizotinib/Placebo***	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A081105	**Must be enrolled in A151216. NSCLC; EGFR Mutant, Resected Tumor. Treatment *Erlotinib/Placebo***	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A221504	**A Randomized, Double-blind, Placebo-controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-small Cell Lung Cancer (Adenocarcinoma)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

NRG LU005	**Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation vs Chemoradiation + Atezolizumab**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1827	**S1827 – MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1900B	**S1900B - A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA5163: INSIGNA	**A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1800A	**A Phase II RANDOMIZED Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1900A	**A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious Brca1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-Map Sub-Study)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

SWOG LungMAP	**A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)**	Screening	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA5162	**Phase II study of AZD9291 (Osimertinib) advanced NSCLC Patients with Exon 20 Insertion**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG LU002	**A Randomized Phase II/III Trial for Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG CC003	**Randomized Phase II/III Trial of Prophylactice Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1900C	**A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub Study)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1929	**Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

CARMEN	**Randomized, Open Label Phase 3 Study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous non-small Cell Lung Cancer patients with CEACAM5 positive tumors**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
MS201923_0050 (DDRiver)	**A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum-resistant small-cell lung cancer**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
ADRIATIC	**AstraZeneca (ADRIATIC): A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with State I-III Limited Disease Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
IPSEN MM-398-01-03-04	**RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) versus Topotecan in Patients with Small Cell Lung Cancer or after Platinum-based First-line Therapy**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
Helsinn (ANAM)	**A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCI for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

CodeBreak200: 20190009	**A Phase III Multicenter, Randomized, Open-label, Active-controlled, Study of AMG 510 vs Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
	An Open Label, Single Arm, Phase IB/II Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-small Cell Lung Cancer (NSCLC) Adenocarcinoma	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554

Lymphoma

Short Name	Comments	Type	Investigator	Contact
A051701	**Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-hit and Double-expressing Lymphomas**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1826	**A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (ADCETRIS) plus AVD in Patients (AGE>/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A051301	**A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma of the Activated B-Cell Subtype**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ANHL12P1	**COG-ANHL12P1: A Randomized Phase II study of *Brentuximab* Vedotin and *Crizatinib* in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL.) Patients Must be <22 Years of Age**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1608	**Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA4181	**A Randomized 3 Arm Phase II Study Comparing 1.) Bendamustine + Rituximab + High Dose Cytarabine (BR/CR), 2.) Bendamustine + Rituximab + High Dose Cytarabine + Acalabrutinib (BR/CR-A) and 3.) Bendamustine + Rituximab + Acalabrutinib (BR-A) in Patients >70 years old with Untreated Mantle Cell Lymphoma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

AALL1731	**A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
CytomX	**CTMX-M-2029-001: A Phase I/II, First-in-human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-Cell Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554

Short Name	Comments	Type	Investigator	Contact
2019-362: Melanoma Surveillance	**A Prospective Standardized Surveillance of Early-Stage Cutaneous Melanoma Based on Anatomic Stage and Molecular Profiling**	Other	**SHORE**: Dr. G. Paul Wright	**Zak Mulder** zachary.mulder@spectrumhealth.org (616) 391-2724
EA6194	**EA6194: Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA6141	**Phase II/III Trial for STAGE III/IV/Unresectable Melanoma; *Nivolumab* + *Ipilimumab* + *Sargramostim* versus *Nivolumab* + *Ipilimumab***	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A091802	**Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA6134	**A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1801	**A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

ARRAY-818-201	**An Open-label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-mutant Melanoma Brain Metastasis**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
Regeneron	**REGN3767-ONC-1613: A Phase I, Open-Label, Dose-Escalation and Cohort Expansion First-in-human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Lag 3 Inhibitor) Administered Alone or in Combination with REGN2810 (PD-1 Inhibitor) in Patients with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554

Short Name	Comments	Type	Investigator	Contact
S1803	**Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)**	Therapy	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
Janssen 54767414MM Y3021	**AURIGA: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com

Sarcoma (Ortho)

Short Name	*Comments*	*Type*	*Investigator*	*Contact*
2011-002: MSTA	**Musculoskeletal Tumor Tissue Acquisition Protocol**	Molecular Profiling	**SHORE**: Dr. Matthew Steensma	**Zak Mulder** zachary.mulder@spectrumhealth.org (616) 391-2724
2012-303: Genetic Outlier	**The Identification of Novel Mutations in Outlier Patients**	Biobanking	**SHORE**: Dr. Matthew Steensma	**Zak Mulder** zachary.mulder@spectrumhealth.org (616) 391-2724
2014-295: NF1 Tissue Harvest	**A Clinical Translation Approach to Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1**	Other	**SHORE**: Dr. Matthew Steensma	**Zak Mulder** zachary.mulder@spectrumhealth.org (616) 391-2724
ALTE16C1	**Effects of Modern Chemotherapy Regimens on spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma**	Other	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ARST1431	**A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Multi-site/Other

Short Name	Comments	Type	Investigator	Contact
SHUB	**The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators**	Biobanking	**SHORE**: Dr. Sandra Cottingham	**Spectrum Health Biorepository** david.chesla@spectrumhealth.org (616) 267-2629
AGCT1531	**A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AGCT1532	**Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1609 DART	**Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A221701	**Alliance A221701, Phase III placebo-controlled trial to evaluate dexamethasone use for everolimus-induced oral stomatitis: prevention versus early treatment approaches: MIST (My Individualized Stomatitis Treatment)**	Symptom Management	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A231601CD	**Improving Surgical Care and Outcomes in Older Cancer Patients through Implementation of An Efficient Pre-Surgical Toolkit (OPTI-surg)**	Cancer Care Delivery	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

A221602	**Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double-Blind, Placebo-Controlled Trial**	Symptom Management	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
DCP-001	**Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**	Screening	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1714	**A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients**	Quality of Life	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 18007	**Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue**	Symptom Management	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
WF-10217	**Work Ability in Young Adult Survivors (WAYS)**	Behavioral	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAZ171	**Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American Women**	Supportive Care	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

A231602CD	**Assessing Financial Difficulty in Patients with Blood Cancers**	Economics of Care	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131-MATCH Screening Trial	**Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma**	Molecular Profiling	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ASCO TAPUR	**Targeted Agent and Profiling Utilization Registry Study: All Drugs Provided**	Molecular Profiling	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NCI PDM 9846	**Patient-derived Models Tissue Procurement Protocol for the National Cancer Institute**	Biobanking	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ACCRU 2018-01	**Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors**	Other	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
APEC1621	**Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Trial)**	Treatment	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
2020-285	**NCI COVID-19 In Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study**	Molecular Profiling	**CRCWM** Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Exact Sciences	**Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors from Twelve Primary Cancer Diagnoses: Breast, Lung, Colorectal, Prostate, Bladder, Uterine, Kidney, Renal, Pelvis, Pancreatic, Liver, Stomach, Ovarian, and Esophageal Cancer**	Biobanking	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
STMW 2020.03	**A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b**	Treatment	**CHCWM** Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
ALX148 (Alexo)	***AT1488001:*** **Phase I, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors or Lymphoma Examining Safety, Pharmacokinetics and Tolerability. Now in Combination Phase II with Pembrolizumab, Rituximab, and Trastuzumab**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554
AVID-100	***AVID100-01:*** **A Phase IA/IIA Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1 in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5554
APG-115	***APG-115*** **: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

Ascentage Pharma: 1252	***APG-1252-US-001:*** **Phase I, Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or Other Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Ascentage Pharma: 1387	***APG-1387-US-001*** **: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1387 as a Single Agent or in Combination with Systemic Anti-cancer Agents in Patients with Advanced Solid Tumors or Hematologic Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
BeiGene USA	***BGB-290-103:*** **A Phase IB Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Bristol-Myers Squibb	***CA031002:*** **A Phase I/II First-in-human Study of BMS-986258 (anti TIM3) Alone and in Combination with Nivolumab in Advanced Malignant Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
COM701-Compugen	***CPG-01-001:*** **A Phase IA/IB Study of COM701 as Monotherapy and in Combination with an Anti-PD-1 Antibody in Subjects with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
COM902-Compugen	***CPG-02-101:*** **A Phase I Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

Coordination Pharmaceuticals: 100	***CPI-CL18-001:*** **A Phase I, First in Human Study Evaluation the Safety, Tolerability, and Pharmacokinetics of CPI-100 via Intravenous Infusion in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Coordination Pharmaceuticals: 200	***CPI-200CL01:*** **A Phase I, First in Human Study Evaluation the Safety, Tolerability, and Pharmacokinetics of CPI-200 via Intravenous Infusion in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Exelixis	***XL092:*** **A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Ikena	***IK-175-001:*** **A Phase I, Open-Label, Dose-Escalation, and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
InhibRx-105	***INBRX-105:*** **An Open-Label, Multicenter, First-in-human, Dose-Escalation Phase I Study of INBRX-105 in Subjects with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
InhibRx-106	***INBRX-106:*** **An Open-Label, Multicenter, First-in-human, Dose-Escalation, Phase I Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

InhibRx-109	***INBRX-109:* An Open-Label, Multicenter, First-in-human, Dose-Escalation, Phase I Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Innovent	***IBI188:* A Phase IA Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-Cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients with Advanced Malignant Tumors and Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Klus	***KL264-01:* A Phase I/II, First-in-human, Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are Refractory to Available Standard Therapies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Expanded Access Loxo	***LOXO-RET-18037:* A Multicenter Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
MacroGenics-018	***MGC018-01:* A Phase I/II, First-in-human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
MacroGenics-019	***MGD019:* A Phase I, First-in-human, Open-Label, Dose-Escalation and Cohort Expansion Study of MGA019, a Bispecific DART Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

Merck-5618	***MK-5618:*** **A Phase IB Multicenter Clinical Study of Selumetinib (MK-5618) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Merck-8353	***MK-8353-013:*** **A Phase IB Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Odonate	***ODO-TE-S101:*** **An Open-label, Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Symphogen	***Sym021-01:*** **A Phase I Open-Label, Multicenter Trial Investigating the Safety, Tolerability and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies or Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Syros	***SY-5609-101:*** **A Phase I Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Selected Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
SCI-CD47-001	***HU5F9-G4*** **: First-in-human Phase I Dose-escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

R3767-ONC-1613	***REGN3767*** **: A Phase I, Open-label, Dose-escalation and Cohort Expansion First-in-human, Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (Anti-PD-1-mAb) in Patients with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
CP-MGA012-01	***MGA012*** **: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
ASN003-101	***ASN003*** **: A Phase I, Open-label, Dose-finding, and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
5F9004	***Hu5F9-G4-Cetuximab*** **: A Phase Ib/II Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
APX-CLN-0011	**A Phase I Study of APX3330 in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
CP-MGA271-03	***Macrogenics Protocol CP-MGA271-03:*** **A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer and Other B7-H3-Expressing Cancers**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

CPI-0209	**A Phase I/II Study of CPI-0209 Monotherapy in Combination with Other Therapy in Patients with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
Sym 021	**Sym 021: A Phase 1, Open-Label, Multicenter Trial investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy and in Combination with either Sym022 (Anti-LAG-3) or SYM023 (Anti-TIM-3) in Patients with Advanced Solid Tumor Malignancies or Lymphomas**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
eFT226	**A Phase I-II Dose-escalation and Cohort-expansion of Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
	Phase 1/2A Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of PF-07104091 as a Single Agent and In Combination Therapy	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
EPZ-6438	**A Phase I, Open-label Multi-dose Two-Part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438), and the Effects of a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat in Subjects with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
NEON-1	**An Open-Label Study of ALPN-202 in Subjects with Advanced Malignancies (NEON-1)**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

	A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Malignancies	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
COM902	**A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
eFT226	**A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous eFT226 in Subjects with Selected Advanced Solid Tumor Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
JTX-8064	**Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin- Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
LYT-200	**A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556
ARRY-558	**A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Anti-Tumor Activity of PF-07284892 (ARRY-558) as a Single Agent and in Combination Therapy in Participants with Advanced Solid Tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556

GEN 1046	**First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors**	Treatment	**START Midwest** Investigators	START Midwest (616) 954-5556